THE TAPE
NBIX · Biotechnology · $16.8B

Neurocrine Biosciences Inc

$165.31▼ −1.25%
Last close
Relative strength
60RS
of 99, against every stock▲ +31 on the month
Powering up
Turning
−14.4%
six months against Biotechnology
52-week range
−11.2%
from the high
$122.14$186.12
Setup
blue skyplayed out
−2.5%
against the pivot at $169.57
No report date on the calendar.
Growth REALProof SHOWN
Quarter to Sep 30, revenue +41% on a year ago
11/16 O 168.39 H 168.62 L 164.81 Vol 1.4M
Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

The four are not in order. That is a description of where the averages sit, not a view about what happens next.

RS60
vs pivot−2.51%
Tightening1.20×
Dry-up0.77×
Up/down vol0.00
From high11%
failed pokeplayed out5 of 9checks
Previous breakout trailed out ▲ +3.40% in May
Powering up
Support and resistance
Support below
$158.39
-4.2% · tested 7× · last 6 sessions ago
Resistance above
$169.50
+2.5% · tested 5× · last 9 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

The base has run 3.2 weeks and fell 8% from its ceiling at its deepest. The pivot is $169.57, and the stock closed 2.5% below it. Its relative strength rating is 60.

Against its industry
TurningBehind its industry over six months, but ahead over one and three.
One month against its industry
+18.4%
Three months against its industry
+14.3%
Six months against its industry
-14.4%

Read against an equal-weighted index of Biotechnology, which is +22.6% against the S&P 500 over six months Partly aligned.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 10.0% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$3.7B
+41.2% year on year
Operating margin
24.0%
Net margin
19.0%
Free cash flow
$1.0B
6.2% of market cap
Price to sales
4.54×
Price to earnings
23.9×

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 2
Key takeaway
Growth with the cash to show for it: the quarter confirms the thesis.
Revenue
$1.1B
+17.1% QoQ · +41.2% YoY
Gross margin
—
Net income
$206.5M
Positive
Free cash flow
$383.6M
Cash generating

What the numbers say

  • Good: Revenue +41.2% year over year, +17.1% on the quarter
  • Good: Profitable: net income $206M, operating margin 29.5%
  • Good: Cash generating: operating cash flow $395M, free cash flow $384M
  • Good: Net cash $642M · cash $642M
Revenue by quarter
Free cash flow
Net income
shares +2.6% in a year · net cash $641.5M

The desk’s own read

Flagged as drifting up since the report

Final read
Growth: REAL · Economic proof: SHOWN
Key question: Does the next quarter repeat this one?
The next test is whether the quarter repeats.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 1 of 46 tracked funds at the end of Q3 2026.

Last quarter: 1 added, 1 sold out.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
Tightening after a sharp runTape · 2026-11-14
range halved after a +20% thrust, at 167.40
No measurable effect: stocks behave like random ones over the next three sessions (887 cases over 60 nights).
Tightening after a sharp runTape · 2026-11-11
range halved after a +18% thrust, at 169.14
No measurable effect: stocks behave like random ones over the next three sessions (887 cases over 60 nights).
Closed above its 20- and 50-day on heavy volumeTape · 2026-11-04
above 20d & 50d on 3.0x volume at 164.85
Mixed: stocks have outrun random stocks by 0.2% over three sessions, not consistently enough to call (1,668 cases over 60 nights). Against their own sector they have lagged by 0.7%.
GappedTape · 2026-11-04
+13.4%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Moved 5%+ up on earningsTape · 2026-11-04
+13.4% on earnings 2026-11-03
No measurable effect: stocks behave like random ones over the next three sessions (604 cases over 42 nights).
Unusual volumeTape · 2026-11-04
8.6 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
Reported resultsFiling · 2026-11-03
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
Earnings date movedEvent · 2026-10-14
2026-11-03 -> 2026-11-02
No measurable effect: stocks behave like random ones over the next three sessions (2,989 cases over 51 nights).

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders
Bought on the open market
0
Sold on the open market
38
$24,815,365 total

Sold: MORROW GEORGE J, Boyer David W., ABERNETHY MATT, BENEVICH ERIC, Norwalk Leslie V, Delaet Ingrid, Lippoldt Darin, SHERWIN STEPHEN A, Cooke Julie, Onyia Jude.

Not counted above: 57 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-11-03 MORROW GEORGE J · Directoroption exercise7,200$386,208
2026-11-03 MORROW GEORGE J · Directorsell100$16,205
2026-11-03 MORROW GEORGE J · Directorsell600$98,225
2026-11-03 MORROW GEORGE J · Directorsell1,226$201,971
2026-11-03 MORROW GEORGE J · Directorsell908$150,461
2026-11-03 MORROW GEORGE J · Directorsell1,466$244,492
2026-11-03 MORROW GEORGE J · Directorsell1,500$251,587
2026-11-03 MORROW GEORGE J · Directorsell1,300$219,092

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What lines up

5 of 9 published checks currently line up. This is a count, not a probability — nothing on this site measures how often a setup works.

Relative strength of 80 or better
Above its 50-day line
Above its 200-day line
Averages fully stacked
Within 5% of its pivot
Range tightening through the base
Volume drying up through the base
More up-volume than down-volume
Within 15% of its 52-week high
What analysts expect
Strong buy4
Buy20
Hold4
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray
3w · 8%

The most recent of 2 completed bases.

Checking your subscription…

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Neurocrine Biosciences Inc (NBIX) — The Tape